Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/10/2010

597 510,127 Licensing fees 266,281 6,641,281 1,565,125 7,440,125 Consulting fees 70,000 70,000 280,000 424,185 --------- --------- --------- --------- Total Revenues 754,122 7,226,882 3,155,757 8,411,780 Costs and expenses: Research and development 135,663 179,479 488,646 439,919 General and administrative 1,347,678 1,350,706 4,832,019 4,191,052 --------- --------- --------- --------- Total costs and expenses 1,483,341 1,530,185 5,320,665 4,630,971 --------- --------- --------- --------- Operating income (loss) (729,219) 5,696,697 (2,164,908) 3,780,809 Other income (expense): Interest Income 27,008 18,239 55,693 107,552 Interest expense - - (39) 46,529 Other, net - - (8,863) 108,730 --------- --------- --------- --------- 27,008 18,239 46,791 262,811 --------- --------- --------- --------- Income (loss) before income tax (7
'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 27, 2015 RnRMarketResearch.com adds ... research report to its store. This report p ... pipeline. The report "Corneal Ulcers - Pipeline Review, ... development for Corneal Ulcers. Corneal Ulcers are primarily ... infections, viral infections & fungal infections. The symptoms ...
(Date:2/26/2015)... ITASCA, Ill. , Feb. 26, 2015  Today ... paper, The psychological and physical side effects ... belief that opioid painkillers, such as Vicodin and Oxycontin, ... "More Americans overdose on prescription painkillers than on ... , president and CEO of NSC. "Yet, these medications ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... , CINCINNATI , Jan. 28, 2010 The Procter ... of six percent for the October - December quarter to $21.0 ... of the Company,s guidance range.  Diluted net earnings per share were ... $1.01 .  Core EPS increased 22 percent to $1.10 ...
... SEATTLE , Jan. 28 Omeros Corporation (Nasdaq: ... Drug Abuse (NIDA) is providing support for the Company,s Addiction ... a Phase 2 clinical study to be conducted by ... program, Omeros is developing proprietary compositions that include peroxisome proliferator-activated ...
Cached Medicine Technology:P&G Reports Accelerated Sales and Unit Volume Growth 2P&G Reports Accelerated Sales and Unit Volume Growth 3P&G Reports Accelerated Sales and Unit Volume Growth 4P&G Reports Accelerated Sales and Unit Volume Growth 5P&G Reports Accelerated Sales and Unit Volume Growth 6P&G Reports Accelerated Sales and Unit Volume Growth 7P&G Reports Accelerated Sales and Unit Volume Growth 8P&G Reports Accelerated Sales and Unit Volume Growth 9P&G Reports Accelerated Sales and Unit Volume Growth 10P&G Reports Accelerated Sales and Unit Volume Growth 11P&G Reports Accelerated Sales and Unit Volume Growth 12P&G Reports Accelerated Sales and Unit Volume Growth 13P&G Reports Accelerated Sales and Unit Volume Growth 14P&G Reports Accelerated Sales and Unit Volume Growth 15P&G Reports Accelerated Sales and Unit Volume Growth 16P&G Reports Accelerated Sales and Unit Volume Growth 17P&G Reports Accelerated Sales and Unit Volume Growth 18P&G Reports Accelerated Sales and Unit Volume Growth 19P&G Reports Accelerated Sales and Unit Volume Growth 20P&G Reports Accelerated Sales and Unit Volume Growth 21P&G Reports Accelerated Sales and Unit Volume Growth 22P&G Reports Accelerated Sales and Unit Volume Growth 23P&G Reports Accelerated Sales and Unit Volume Growth 24P&G Reports Accelerated Sales and Unit Volume Growth 25P&G Reports Accelerated Sales and Unit Volume Growth 26P&G Reports Accelerated Sales and Unit Volume Growth 27P&G Reports Accelerated Sales and Unit Volume Growth 28P&G Reports Accelerated Sales and Unit Volume Growth 29Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program 2Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program 3Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program 4
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... to announce that they have officially relaunched their website. ... more user-friendly, but it contains a new section about ... access to read the full biographies of each Friedman ... portion of the website was designed to provide our ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... capable by the State of Illinois, enabling potential stroke ... Hospital. , The hospital was required to submit data ... stroke according to national standards of care for stroke ... bypass hospitals not designated as an Emergent Stroke Ready ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... shows that fetal cell transplantation for patients with ... of their medications altogether.// ,Parkinson’s disease ... Patients with Parkinson’s lack the chemical dopamine, which ... transplanting aborted human fetal tissue to replace the ...
... to the latest issue of Harvard Heart Letter, testing of ... Clinical testing of eye can predict the condition of the ... ,In a study headed by Dr. John I. Loewenstein, a ... relationship has been drawn between changing conditions of blood vessels ...
... use for cell phones that come complete with cameras: ... phone cameras to send pictures of wounds to specialists ... the wounds from the photos. ,The study involved ... seen in an outpatient clinic. Investigators had a physician ...
... new study shows that infants born under 5.5 pounds ... for developing // type 2 diabetes later in life. ... the only cause of prenatal malnourishment. Abnormal development of ... pressure, which damages vessels can also lead to malnourishment ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... Dental Society's 140th Midwinter Meeting that begins in US ... over can take a peek to some very innovative ... display there. The convention is also one of the ... ,The showcase of products from 46 countries will ...
Cached Medicine News:
For the quantitative in vitro determination of Potassium in serum or plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Valproic Acid in human serum...
For the quantitative in vitro determination of Microalbumin in human urine....
Medicine Products: